These observations have implications for gene therapy that use genome editing technology to correct the ACTA2 p.Arg179 variants in SMCs: this approach may not prevent MMD cerebrovascular occlusive lesions unless most, if not, all, the hypermigratory SMCs are edited to correct the mutation. This evidence concerns the gene ACTA2 and multiminicore myopathy.